Sarcopenia and myosteatosis are associated with low survival in patients receiving lenvatinib for unresectable hepatocellular carcinoma

Purpose: To investigate the association of skeletal muscle mass and quality with survival outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with lenvatinib (LEN). Methods: In this retrospective study, LEN-treated patients with HCC were enrolled. Sarcopenia and myosteatosis we...

詳細記述

書誌詳細

出版年:	Journal of the Formosan Medical Association
主要な著者:	Pei-Jui Luo, Kai-I Chuang, Cheng-Fu Ni, Hsiao-Yu Yeh, Ming-Shun Wu, Yao-Yu Hsieh, Wei-Yu Kao, Chih-Horng Wu
フォーマット:	論文
言語:	英語
出版事項:	Elsevier 2025-09-01
主題:	Computed tomography Hepatocellular carcinoma Myosteatosis Prognosis Lenvatinib Sarcopenia
オンライン･アクセス:	http://www.sciencedirect.com/science/article/pii/S0929664625000014